With the understanding of its structure, scientists can tailor TRACeR-I to better suit individual patient needs, leading to more precise immune responses and increased efficacy in combating cancer cells. This breakthrough not only has the potential to enhance cell-based immunotherapy and protein-guided immunotherapy but also opens up possibilities for the development of other protein platforms with greater capabilities in manipulating immune responses. Furthermore, the knowledge gained from TRACeR-I’s structure could have applications in various autoimmune diseases and inflammatory conditions beyond cancer treatment. Overall, the unraveling of TRACeR-I’s molecular structure has significant implications in advancing cancer treatment possibilities and the field of immunotherapy as a whole.